| Literature DB >> 29423190 |
Appiah-Korang Labi1, Noah Obeng-Nkrumah2, Edmund Tetteh Nartey3, Stephanie Bjerrum4, Nii Armah Adu-Aryee5, Yaw Adjei Ofori-Adjei6, Alfred E Yawson7, Mercy J Newman8.
Abstract
Background: The global rise and spread of antibiotic resistance is limiting the usefulness of antibiotics in the prevention and treatment of infectious diseases. The use of antibiotic stewardship programs guided by local data on prescribing practices is a useful strategy to control and reduce antibiotic resistance. Our objective in this study was to determine the prevalence and indications for use of antibiotics at the Korle-Bu Teaching Hospital Accra, Ghana.Entities:
Keywords: Africa; Antibiotic; Antibiotic stewardship; Ghana; Point prevalence
Mesh:
Substances:
Year: 2018 PMID: 29423190 PMCID: PMC5787245 DOI: 10.1186/s13756-018-0299-z
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Prevalence rates of antibiotic use across departments/units
| Department | Patients on antibiotics | Antibiotic prescriptions | ||||
|---|---|---|---|---|---|---|
| Number | % prevalence [95% CI] | Parenteral | Oral | Total | % prevalence [95% CI] | |
| Obstetrics (n = 214) | 77 | 36.0 [29.5-42.8] | 46 (33.8) | 90 (66.2) | 136 | 16.5[13.8-19.5] |
| Child Health (n = 111) | 77 | 69.4 [59.9-77.8] | 120 (85.1) | 21(14.9) | 141 | 22.5[19.5-25.9] |
| Medicine ( | 53 | 50.0 [40.1-59.9] | 65 (64.4) | 36 (35.6) | 101 | 16.5[13.8-19.5] |
| Orthopaedics (n = 84) | 48 | 57.1 [45.9-67.9] | 26 (35.6) | 47 (64..4) | 73 | 13.3[10.4-16.2 |
| General Surgery (n = 55) | 33 | 56.9 [43.2-69.8] | 28 (58.9) | 24 (46.2) | 52 | 8.6[8.7-11.4] |
| Paediatric Surgery (n = 22) | 20 | 90.9 [70.8-98.9] | 32 (84.2) | 6 (15.8) | 38 | 5.8[4.2-8.6] |
| Gynaecology (n = 38) | 17 | 44.7 [28.6-61.7] | 17 (53.7) | 13(43.3) | 30 | 4.5[3.1-6.4] |
| Neuro-surgery (n = 23) | 12 | 52.2 [30.6-73.2] | 21 (87.5) | 3 (12.5) | 24 | 3.6[2.4-53.8] |
| Urology (n = 24) | 11 | 45.8 [29.8-74.3] | 11 (68.8) | 5 (31.2) | 16 | 2.3[1.4-3.8] |
| All departments (n-677) | 348 | 51.4 [47.6-55.2] | 366 (59.9)b | 245(40.1)a | 611 | |
Prevalence was determined by dividing the number of inpatients on antibiotics at the time of survey by the total of patients on admission; CI, confidence interval; b > a at p < 0.05
Fig. 1Number of antibiotics used per patient in the surveyed departments/units of Korle-Bu Teaching Hospital. A significant majority of patients on antibiotics received > 1 antibiotic regimen
Proportion of prescribed antibiotics (ATC level 5) by Departments/units
| Drug name (generic) | Department/Unit | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Child Health | Medicine | Obstetrics | Gynaecology | Orthopaedics | General Surgery | Neuro-surgery | Urology | Paediatric Surgery | |
| n, % | n, %1 | n, % | n, % | n, % | n, % | n, %1 | n, %1 | n, %1 | ||
| Metronidazole | 107 (17.5) | 4 (2.8) | 13 (12.9) | 54 (39.7) | 9 (30.0) | 3(4.1) | 9 (17.3) | 4 (16.7) | 2 (12.5) | 9 (23.7) |
| Amoxicillin- clavulanic acid | 82 (13.4) | 1 (0.7) | 7 (6.9) | 48 (35.3) | 8 (26.7) | 1 (1.4) | 12 (23.1) | 2 (8.3) | 1 (6.3) | 2 (5.3) |
| Ceftriaxone | 74 (12.1) | 20 (14.2) | 27 (26.7) | 4 (2.9) | 4 (13.3) | 1 (1.4) | 2 (3.9) | 7 (29.2) | 1 (6.3) | 8 (21.1) |
| Cefuroxime | 61 (10.0) | 6 (4.3) | 2 (2.0) | 13 (9.6) | 5 (16.7) | 28 (38.4) | 5 (9.6) | 1 (4.2) | – | 1 (2.6) |
| Cloxacillin | 52 (8.5) | 28 (19.9) | 10 (9.9) | 1 (0.7) | – | 5 (6.9) | – | 6 (25.0) | – | 2 (5.3) |
| Clindamycin | 49 (8.0) | 10 (7.1) | 3 (2.9) | 4 (2.9) | 1 (3.3) | 25 (30.1) | 7 (13.5) | 1 (4.2) | 1 (6.3) | – |
| Gentamicin | 46 (7.5) | 30 (21.3) | 3 (2.9) | 2 (1.5) | 1 (3.3) | 1 (1.4) | 2 (3.9) | 1 (4.2) | – | 6 (15.8) |
| Ciprofloxacillin | 39 (6.4) | 6 (4.3) | 7 (6.9) | – | 1 (3.3) | 9 (12.3) | 8 (15.4) | 1 (4.2) | 5 (31.3) | 2 (5.3) |
| Azithromycin | 21 (3.4) | – | 13 (12.9) | 5 (3.9) | 1 (3.3) | 1 (1.4) | – | – | 1 (6.3) | – |
| Co-trimoxazole | 14 (2.3) | 7 (5.0) | 7 (6.9) | – | – | – | – | – | – | |
| Meropenem | 12 (2.0) | 2 (1.4) | 1 (1.0) | – | – | – | 2 (3.9) | – | 4 (25.0) | 3 (7.9) |
| Amikacin | 8 (1.3) | 7(5.0) | – | – | – | – | – | Q | -a | – |
| Ampicillin | 10 (1.6) | 7 (5.0) | – | – | – | – | – | – | – | 3 (7.9) |
| Crystal penicillin | 7 (1.2) | 6 (4.3) | 1 (1.0) | – | – | – | – | – | – | – |
| Cefotaxime | 6 (1.0) | 6 (4.3) | – | – | – | – | – | – | – | – |
| Levofloxacin | 5 (0.8) | – | 3 (3.0) | – | – | 1 (1.4) | 1 (1.9) | – | – | – |
| Erythromycin | 5 (0.8) | – | 1 (1.0) | 4 (2.9) | – | – | – | – | – | – |
| Clarithromycin | 3 (0.5) | – | – | – | – | – | 3 (5.7) | – | – | – |
| Nitrofuratoin | 2 (0.3) | – | – | – | – | 1 (1.4) | – | – | 1 (6.3) | – |
| Ceftazidine | 2 (0.3) | – | 1 (1.0) | – | – | – | – | – | – | 1 (2.6) |
| Amoxicillin | 1 (0.2) | – | – | – | – | – | 1 (1.9) | – | – | – |
| Cefixime | 1 (0.2) | – | – | 1 (0.7) | – | – | – | – | – | – |
| Doxycycline | 1 (0.2) | – | 1 (1.0) | – | – | – | – | – | – | – |
| Cefpodoxime | 1 (0.2) | – | – | – | – | – | – | – | – | 1 (2.6) |
| Nalidixic acid | 1 (0.2) | 1 (0.7) | – | – | – | – | – | – | – | – |
| Vancomycin | 1 (0.2) | – | 1 (1.0) | – | – | – | – | – | – | – |
| Total | 611 | 141 | 101 | 136 | 30 | 73 | 52 | 24 | 16 | 38 |
ATC, Anatomic therapeutic classification; n=number; %, prevalence
Fig. 2Top five antibiotic use in 2000 and 2017 at KBTH. Figures on antibiotic use in 2000 based on data by Newman, 2009 [17]
Proportion of prescribed antibiotics (ATC level 5) by indication
| Drug name (generic) | Total, % | Community acquired | Hospital acquired | Surgical prophylaxis | Medical prophylaxis |
|---|---|---|---|---|---|
| n, % | n, % | n, % | n, % | ||
| Metronidazole | 107 (17.5) | 22 (9.0) | 16 (12.5) | 66 (32.2) | 3 (9.1) |
| Amoxicillin- clavulanic acid | 82 (13.4) | 18 (7.4) | 9 (7.0) | 53 (25.9) | 2 (13.4) |
| Ceftriaxone | 74 (12.1) | 44 (18.0) | 16 (12.5) | 13 (6.3) | 1 (3.0) |
| Cefuroxime | 61 (10.0) | 24 (9.8) | 7 (5.5) | 28 (13.7) | 2 (6.1) |
| Cloxacillin | 52 (8.5) | 26 (10.6) | 15 (11.7) | 8 (3.9) | 3 (9.1) |
| Clindamycin | 49 (8.0) | 21 (8.6) | 13 (10.2) | 15 (7.3 | – |
| Gentamicin | 46 (7.5) | 26 (10.6) | 13 (10.2) | 5 (2.4) | 2 (6.1) |
| Ciprofloxaciin | 39 (6.4) | 17 (6.9) | 14 (10.9) | 8 (3.9) | – |
| Azithromycin | 21 (3.4) | 16 (6.5) | 3 (2.3) | 2 (1.0) | – |
| Co-trimoxazole | 14 (2.3) | 3 (1.2) | 1 (0.8) | – | 10 (30.3) |
| Meropenem | 12 (2.0) | 2 (0.8) | 9 (7.0) | 1 (0.5) | – |
| Amikacin | 8 (1.3) | 3 (1.2) | 3 (2.3) | – | 2 (6.1) |
| Ampicillin | 10 (1.6) | 7 (2.9) | – | 2 (1.0) | 1 (3.0) |
| Crystal penicillin | 7 (1.2) | 2 (0.8) | 2 (1.6) | – | 3 (9.1) |
| Cefotaxime | 6 (1.0) | 5 (2.0) | 1 (0.8) | – | – |
| Levofloxacin | 5 (0.8) | 1 (0.4) | 3 (2.3) | 1 (0.5) | – |
| Erythromycin | 5 (0.8) | 2 (0.8) | – | – | 3 (9.1) |
| Clarithromycin | 3 (0.5) | 2 (0.8) | – | 1 (0.5) | – |
| Nitrofuratoin | 2 (0.3) | – | 1 (0.8) | 1 (0.5) | – |
| Ceftazidine | 2 (0.3) | – | 2 (1.6) | – | – |
| Amoxicillin | 1 (0.2) | 1 (0.4) | – | – | – |
| Cefixime | 1 (0.2) | – | – | 1 (0.5) | – |
| Doxycycline | 1 (0.2) | 1 (0.4) | – | – | – |
| Cefpodoxime | 1 (0.2) | – | 1 (0.8) | – | – |
| Nalidixic acid | 1 (0.2) | 1 (0.4) | – | – | – |
| Vancomycin | 1 (0.2) | 1 (0.4) | – | – | – |
| Total | 611(100) | 245 | 128 | 205 | 33 |
ATC, Anatomic therapeutic classification, n number; %, prevalence
Proportion of prescribed antibiotics (ATC level 5) by anatomic site
| Drug name (generic) | Anatomic sites | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | CNS | OTH | UT | GIT | SSTBJ | GUOB | RESP | Undefined | |
| n, % | n, % | n, % | n, % | n, % | n, % | n, % | |||
| Metronidazole | 107 | 10 (9.3) | – | – | 15 (14.0) | 6 (5.6) | 62 (57.9) | 10 (9.3) | 4 (3.7) |
| Amoxicillin- clavulanic acid | 82 | 1 (1.2) | 1 (1.2) | – | 2 (2.4) | 8 (9.8) | 57 (69.5) | 10 (12.2) | 3 (3.7) |
| Ceftriaxone | 74 | 16 (21.6) | 2 (2.7) | 1 (1.4) | 9 (12.2) | 4 (5.4) | 8 (10.8) | 24 (32.4) | 10 (13.5) |
| Cefuroxime | 61 | 1 (1.6) | – | 4 (6.6) | 5 (8.2) | 27 (44.8) | 9 (14.8) | 11 (18.0) | 4 (6.6) |
| Cloxacillin | 52 | 13 (25.0) | 1 (1.9) | – | 2 (3.9) | 13 (25.0) | – | – | 23 (44.2) |
| Clindamycin | 49 | 1 (2.0) | – | – | 1 (2.0) | 36 (73.5) | 2 (4.1) | 5 (10.2) | 4 (8.2) |
| Gentamicin | 46 | 3 (6.5) | 2 (4.3) | 1 (2.2) | 3 (6.5) | 6 (13.0) | 1 (2.2) | 5 (10.9) | 25 (54.4) |
| Ciprofloxacin | 39 | 1 (2.6) | – | 5 (12.8) | 9 (23.1) | 13 (33.3) | 6 (15.4) | 2 (5.1) | 3 (7.7) |
| Azithromycin | 21 | 1 (4.8) | – | – | – | – | 1 (4.8) | 18 (85.7) | 1 (4.8) |
| Co-trimoxazole | 14 | 2 (14.3) | – | – | – | – | – | 11 (78.6) | 1 (7.1) |
| Meropenem | 12 | – | – | 4 (33.3) | 1 (8.3) | 1 (8.3) | 1 (8.3) | 1 (8.3) | 4 (33.3) |
| Amikacin | 8 | 1 (12.5) | – | – | – | – | – | – | 7 (87.5) |
| Ampicillin | 10 | – | – | – | 2 (20.0) | – | – | 3 (30.0) | 5 (50.0) |
| Crystal penicillin | 7 | – | 1 (14.3) | – | 1 (14.3) | – | 1 (14.3) | 3 (42.9) | 1 (14.3) |
| Cefotaxime | 6 | 2 (33.3) | – | – | – | – | – | – | 4 (66.7) |
| Levofloxacin | 5 | – | – | 1 (25.0) | – | 2 (40.0) | – | – | 2 (40.0) |
| Erythromycin | 5 | – | – | – | – | 1 (20.0) | 4 (80.0) | – | – |
| Clarithromycin | 3 | – | – | – | 3 (100) | – | – | – | – |
| Nitrofuratoin | 2 | – | – | 1 (50.0) | – | 1 (50.0) | – | – | – |
| Ceftazidine | 2 | – | – | 1 (50.0) | – | – | – | 1 (50.0) | – |
| Amoxicillin | 1 | – | – | – | 1 (100) | – | – | – | – |
| Cefixime | 1 | – | – | – | – | – | 1 (100) | – | – |
| Doxycycline | 1 | – | – | – | – | – | 1 (100) | – | – |
| Cefpodoxime | 1 | – | – | – | – | 1 (100) | – | – | – |
| Nalidixic acid | 1 | – | – | 1 (100) | – | – | – | – | – |
| Vancomycin | 1 | 1 (100) | – | – | – | – | – | – | – |
| Total | 611 | 52 | 7 | 19 | 54 | 119 | 154 | 104 | 101 |
CNS central nervous system; OTH, others; UT urinary tract, GIT gastrointestinal tract, SSTBJ skin, soft tissue, bone and joints, GUOB genitourinary and obstetrics, RESP respiratory; n, number; %, prevalence